Appointments at Sanofi, GSK, Eli Lilly and Watson Pharmaceuticals – People on the move

By Nick Taylor

- Last updated on GMT

Related tags: Chief financial officer, Management occupations, Board of directors, Eli lilly, Gsk

in-PharmaTechnologist presents its latest round-up of movements in the pharma sector including appointments at Sanofi, GSK, Eli Lilly and Watson Pharmaceuticals.

Sanofi-aventis​ has named Richard Klausne​r as chairman of the strategic development and scientific advisory council. Klausner is the former executive director for global health at the Bill and Melinda Gates Foundation and has also worked as director of the National Cancer Institute (NCI).

Michael McClurg​ has joined Stellar Biotechnologies​ as vice president (VP), business development and marketing. McClurg has previously worked at Chemtron Biotech, Quidel, Maxim Pharmaceuticals and Prometheus Laboratories.

GlaxoSmithKline​ (GSK) has appointed Judy Lewent​ and Stacey Cartwright​ as non-executive directors. Lewis is a former Merck & Co EVP and Cartwright is EVP and chief financial officer of Burberry Group.

Greg Plowman​ has been hired as VP, oncology research at Eli Lilly​ and SVP at ImClone​. The dual role gives Plowman oversight of oncology research at Lilly and its subsidiary ImClone. In a 25 year cancer research career Plowman has worked at Genentech, Bristol-Myers Squibb, Pharmacia and more.

Watson Pharmaceuticals​ has promoted David Buchen​ to EVP, general counsel and secretary and Todd Joyce to EVP, chief financial officer. Both have worked at Watson since the late 1990s.

Peter Traber​ has been named president and CEO of Pro-Pharmaceuticals​. Taber was appointed interim chief medical officer in 2010 and will now succeed Theodore Zucconi, who continues on the board of directors, as CEO. Traber has previously worked at GSK.

Progenics Pharmaceuticals​ has promoted its president Mark Baker​ to CEO. Also, Paul Maddon has been appointed to the newly created position of vice chairman of the board of directors, Maddon will continue as chief scientific officer.

Related topics: Markets & Regulations

Related news

Show more

Follow us

Products

View more

Webinars